“Bimekizumab Continuous Maintenance of Eesponse at Every Visit Through Two Years in Patients with Moderate to Severe Plaque Psoriasis: Post-hoc Results from Five Phase 3/3b Trials” (2024) SKIN The Journal of Cutaneous Medicine, 8(1), p. s303. doi:10.25251/skin.8.supp.303.